BioTuesdays

Tag - SVB Leerink

ContraFect Logo

SVB Leerink starts ContraFect at OP; PT $14

SVB Leerink initiated coverage of ContraFect (NASDAQ:CFRX) with an “outperform” rating and sum-of-the-parts price target of $14. The stock closed at $3.90 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that...

SVB Leerink starts Aligos Therapeutics at OP; PT $29

SVB Leerink initiated coverage of Aligos Therapeutics (NASDAQ:ALGS) with an “outperform” rating and $29 price target. The stock closed at $15.31 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that Aligos is unique among...

scPharmaceuticals

SVB Leerink starts scPharmaceuticals at MP; PT $6

SVB Leerink launched coverage of scPharmaceuticals (NASDAQ:SCPH) with a “market perform” rating sum-of-the-parts PT of $6. The stock closed at $5.95 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that, among other...

Analysts start RxSight at buy

Analysts for BTIG and SVB Leerink launched coverage of RxSight (NASDAQ:RXST) with “buy” ratings and price targets of $28 and $20, respectively. The stock closed at $11.94 on Aug. 23. RxSight has developed the Light...

Amryt-Logo

SVB Leerink starts Amryt Pharma at OP: PT $22

SVB Leerink initiated coverage of Amryt Pharma PLC (NASDAQ:AMYT) with an “outperform” rating and price target of $22. Analyst Mani Foroohar, M.D., writes that Amryt’s model of acquiring niche commercial or near...

SVB Leerink starts RAPT Therapeutics at OP; PT $49

SVB Leerink launched coverage of RAPT Therapeutics (NASDAQ:RAPT) with an “outperform” rating and a $49 price target. The stock closed at $33.07 on Aug. 11. RAPT is a clinical-stage biopharmaceutical company developing...

SVB Leerink starts Elevation Oncology at OP; PT $20

SVB Leerink launched coverage of Elevation Oncology (NASDAQ:ELEV) with an “outperform” rating and $20 price target. The stock closed at $12.10 on July 19. Elevation is a clinical development-stage biotech company...

F-star logo

SVB Leerink starts F-Star Therapeutics at OP; PT $39

SVB Leerink launched coverage of F-Star Therapeutics (NASDAQ:FSTX) with an “outperform” rating and $39 price target. The stock closed at $7.34 on July 7. F-star’s pipeline generates drug candidates that work with...

SVB Leerink starts NeuroPace at OP; PT $25

SVB Leerink initiated coverage of Neuropace (NASDAQ:NPCE) with an “outperform” rating and $25 price target. The stock closed at $20.91 on May 14. “To us, NeuroPace represents a top-tier growth profile SMID-cap MedTech...